Rule 2.12 Announcement – Horizon Therapeutics plc

Rhea-AI Summary

Horizon Therapeutics, as of January 11, 2023, reports a total of 228,768,464 ordinary shares with a nominal value of $0.0001 each, plus 40,000 deferred shares of €1.00. They hold 384,366 shares as treasury shares. The company has outstanding options for 4,803,451 ordinary shares and rights for an aggregate of 1,868,932 ordinary shares from restricted and performance stock units. Horizon is committed to developing therapies for rare and autoimmune diseases, with shares traded under the ticker HZNP on Nasdaq.

Positive

• Horizon has a solid issuance of 228,768,464 ordinary shares, providing a strong equity base.
• The company holds a significant number of outstanding options (4,803,451) which may attract investor interest.
• Horizon focuses on critical needs in rare and autoimmune disease markets, indicating potential for growth.

Negative

• None.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

DUBLIN--(BUSINESS WIRE)-- In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on January 11, 2023, Horizon’s issued ordinary share capital is comprised of 228,768,464 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”. The International Securities Identification Number for these securities is IE00BQPVQZ61.

The Company confirms that as of January 11, 2023, there were outstanding options to purchase up to 4,803,451 Ordinary Shares and outstanding restricted stock units and performance stock units conferring on their holders vested or unvested rights to convert into, or receive, up to an aggregate of 1,868,932 Ordinary Shares and incremental restricted stock units to be issued of 4,393,081 Ordinary Shares.

About Horizon

Horizon Therapeutics plc is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com.

Enquiries

Horizon Investor Relations
investor-relations@horizontherapeutics.com

Statement Required by the Irish Takeover Rules

The directors of Horizon accept responsibility for the information contained in this document. To the best of the knowledge and belief of the directors of Horizon (who have taken all reasonable care to ensure such is the case), the information contained in this document for which they respectively accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

Dealing Disclosure Requirements

Under the provisions of Rule 8.3(b) of the Irish Takeover Rules, if any person is, or becomes, ‘interested’ (directly or indirectly) in 1% or more of any class of ‘relevant securities’ of Horizon (including by means of an option in respect of, or a derivative referenced to, any such ‘relevant securities’), that person must publicly disclose all ‘dealings’ in any ‘relevant securities’ of Horizon during the ‘offer period,’ by not later than 3:30 p.m. (E.T.) on the ‘business day’ following the date of the relevant transaction.

If two or more persons co-operate on the basis of any agreement either express or tacit, either oral or written, to acquire an ‘interest’ in ‘relevant securities’ of Horizon, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.

A disclosure table, giving details of the companies in whose ‘relevant securities’ and ‘dealings’ should be disclosed can be found on the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie.

‘Interests’ in securities arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an ‘interest’ by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel’s website. If you are in any doubt as to whether or not you are required to disclose a ‘dealing’ under Rule 8, please consult the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel at telephone number +353 1 678 9020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005852/en/

Investor Relations

investor-relations@horizontherapeutics.com

Source: Horizon Therapeutics plc

FAQ

What is the current share capital of Horizon Therapeutics as of January 2023?

As of January 11, 2023, Horizon's issued ordinary share capital consists of 228,768,464 ordinary shares.

How many shares does Horizon hold as treasury shares?

Horizon holds 384,366 ordinary shares as treasury shares.

What is the ticker symbol for Horizon Therapeutics?

Horizon Therapeutics is traded under the ticker symbol 'HZNP' on the Nasdaq.

How many outstanding options does Horizon have for ordinary shares?

Horizon has outstanding options to purchase up to 4,803,451 ordinary shares.

What types of shares are included in Horizon's issued share capital?

Horizon’s issued share capital includes ordinary shares and 40,000 deferred ordinary shares.